GPT and Hypertension: The most frequently reported treatment-related AEs (≥10%) were aspartate transaminase elevation (n = 77, 96.2%), alanine transaminase elevation (n = 76, 95.0%), fever (n = 52, 65.0%), anorexia (n = 48, 60.0%), abdominal pain (n = 43, 53.8%), hand-foot skin reaction (n = 38, 47.5%), hypertension (n = 32, 40.0%), fatigue (n = 30, 37.5%), diarrhea (n = 24, 30.0%), weight loss (n = 24, 30.0%), rash or desquamation (n = 20, 25.0%), elevated bilirubin (n = 11, 13.8%), and proteinuria (n = 8, 10.0%).